The Combination of Dehydroepiandrosterone, Transdermal Testosterone, and Growth Hormone As an Adjuvant Therapy in Assisted Reproductive Technology Cycles in Patients Aged Below 40 Years with Diminished Ovarian Reserve

Overview

Journal Turk J Obstet Gynecol

Specialty Gynecology & Obstetrics

Date 2017 Sep 16

PMID 28913044

Citations 4

Authors

Bulent Haydardedeoglu

Ahmet Zeki Isik

Esra Bulgan Kilicdag

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate to the efficacy of testosterone, dehydroepiandrosterone (DHEA) and growth hormone (GH) supplementations in patients with diminished ovarian reserve (DOR) in assisted reproductive technology (ART) cycles.

Materials And Methods: A retrospective cohort including 33 women with 81 ART cycles were aged and ovarian reserve matched 52 women with 102 conventional in vitro fertilization (IVF)/intra-cytoplasmic sperm injection (ICSI) protocol. Administration of DHEA for 12 weeks and transdermal testosterone for 4 weeks as pretreatment adjuvant and luteal start GH in DOR patient treatment arm compared to conventional IVF/ICSI cycles.

Results: The number of follicles >14 mm, number of oocytes, number of metaphase 2 oocytes and fertilisation rate were significantly higher in ISIK protocol (IP). The clinical pregnancy rate (CPR) per embryo transfer of the IP was 38.2% (13/34). The cancellation rate of cycles decreased significantly from 54.5 % (24/44) to 8.1% (3/37) with the IP, while the OPR was 35.3% (12/34).

Conclusions: Our study has shown that even the poorest responders could achieve clinical pregnancy after inducing ovarian folliculogenesis with a combination of transdermal testosterone, DHEA and GH.

Citing Articles

Preliminary report of intraovarian injections of autologous platelet-rich plasma (PRP) in extremely poor prognosis patients with only oocyte donation as alternative: a prospective cohort study.

Barad D, Albertini D, Molinari E, Gleicher N Hum Reprod Open. 2022; 2022(3):hoac027.

PMID: 35795849 PMC: 9247703. DOI: 10.1093/hropen/hoac027.

Long-term Hyperandrogenemia and/or Western-style Diet in Rhesus Macaque Females Impairs Preimplantation Embryogenesis.

Ravisankar S, Murphy M, Redmayne-Titley N, Davis B, Luo F, Takahashi D Endocrinology. 2022; 163(4).

PMID: 35192701 PMC: 8962721. DOI: 10.1210/endocr/bqac019.

Live birth outcomes of vitrified embryos generated under growth hormone stimulation are improved for women categorized as poor-prognosis.

Keane K, Ye Y, Hinchliffe P, Regan S, Dhaliwal S, Yovich J Clin Exp Reprod Med. 2019; 46(4):178-188.

PMID: 31739659 PMC: 6919205. DOI: 10.5653/cerm.2019.00206.

DHEA Supplementation Confers No Additional Benefit to that of Growth Hormone on Pregnancy and Live Birth Rates in IVF Patients Categorized as Poor Prognosis.

Keane K, Hinchliffe P, Rowlands P, Borude G, Srinivasan S, Dhaliwal S Front Endocrinol (Lausanne). 2018; 9:14.

PMID: 29445356 PMC: 5797762. DOI: 10.3389/fendo.2018.00014.

References

Weissman A, Horowitz E, Ravhon A, Golan A, Levran D . Dehydroepiandrosterone supplementation increases baseline follicular phase progesterone levels. Gynecol Endocrinol. 2011; 27(12):1014-7. DOI: 10.3109/09513590.2011.569611. View

Gleicher N, Kim A, Weghofer A, Kushnir V, Shohat-Tal A, Lazzaroni E . Hypoandrogenism in association with diminished functional ovarian reserve. Hum Reprod. 2013; 28(4):1084-91. DOI: 10.1093/humrep/det033. View

Strauss S, Greve T, Ernst E, Fraidakis M, Grudzinskas J, Andersen C . Administration of DHEA augments progesterone production in a woman with low ovarian reserve being transplanted with cryopreserved ovarian tissue. J Assist Reprod Genet. 2014; 31(6):645-9. PMC: 4048379. DOI: 10.1007/s10815-014-0214-3. View

Sunkara S, Pundir J, Khalaf Y . Effect of androgen supplementation or modulation on ovarian stimulation outcome in poor responders: a meta-analysis. Reprod Biomed Online. 2011; 22(6):545-55. DOI: 10.1016/j.rbmo.2011.01.015. View

Duffy J, Ahmad G, Mohiyiddeen L, Nardo L, Watson A . Growth hormone for in vitro fertilization. Cochrane Database Syst Rev. 2010; (1):CD000099. PMC: 7058116. DOI: 10.1002/14651858.CD000099.pub3. View

Isik A, Caglar G, Sozen E, Akarsu C, Tuncay G, Ozbicer T . Single-dose GnRH agonist administration in the luteal phase of GnRH antagonist cycles: a prospective randomized study. Reprod Biomed Online. 2009; 19(4):472-7. DOI: 10.1016/j.rbmo.2009.04.001. View

Narkwichean A, Jayaprakasan K, Maalouf W, Hernandez-Medrano J, Pincott-Allen C, Campbell B . Effects of dehydroepiandrosterone on in vivo ovine follicular development. Hum Reprod. 2013; 29(1):146-54. DOI: 10.1093/humrep/det408. View

Gonzalez-Comadran M, Duran M, Sola I, Fabregues F, Carreras R, Checa M . Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis. Reprod Biomed Online. 2012; 25(5):450-9. DOI: 10.1016/j.rbmo.2012.07.011. View

Yeung T, Li R, Lee V, Ho P, Ng E . A randomized double-blinded placebo-controlled trial on the effect of dehydroepiandrosterone for 16 weeks on ovarian response markers in women with primary ovarian insufficiency. J Clin Endocrinol Metab. 2012; 98(1):380-8. DOI: 10.1210/jc.2012-3071. View

10.

Pandian Z, McTavish A, Aucott L, Hamilton M, Bhattacharya S . Interventions for 'poor responders' to controlled ovarian hyper stimulation (COH) in in-vitro fertilisation (IVF). Cochrane Database Syst Rev. 2010; (1):CD004379. DOI: 10.1002/14651858.CD004379.pub3. View

11.

Vendola K, Zhou J, Adesanya O, Weil S, Bondy C . Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest. 1998; 101(12):2622-9. PMC: 508852. DOI: 10.1172/JCI2081. View

12.

Ferraretti A, La Marca A, Fauser B, Tarlatzis B, Nargund G, Gianaroli L . ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. 2011; 26(7):1616-24. DOI: 10.1093/humrep/der092. View

13.

Kolibianakis E, Venetis C, Diedrich K, Tarlatzis B, Griesinger G . Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in-vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update. 2009; 15(6):613-22. DOI: 10.1093/humupd/dmp026. View

14.

Lu Q, Shen H, Li Y, Zhang C, Wang C, Chen X . Low testosterone levels in women with diminished ovarian reserve impair embryo implantation rate: a retrospective case-control study. J Assist Reprod Genet. 2014; 31(4):485-91. PMC: 3969473. DOI: 10.1007/s10815-014-0186-3. View

15.

Narkwichean A, Maalouf W, Campbell B, Jayaprakasan K . Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished ovarian reserve: a meta-analysis. Reprod Biol Endocrinol. 2013; 11:44. PMC: 3663765. DOI: 10.1186/1477-7827-11-44. View

16.

Bosdou J, Venetis C, Kolibianakis E, Toulis K, Goulis D, Zepiridis L . The use of androgens or androgen-modulating agents in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis. Hum Reprod Update. 2012; 18(2):127-45. DOI: 10.1093/humupd/dmr051. View

17.

de Los Santos M, Garcia-Laez V, Beltran D, Labarta E, Zuzuarregui J, Alama P . The follicular hormonal profile in low-responder patients undergoing unstimulated cycles: Is it hypoandrogenic?. Hum Reprod. 2012; 28(1):224-9. DOI: 10.1093/humrep/des349. View

18.

Gleicher N, Weghofer A, Barad D . Dehydroepiandrosterone (DHEA) reduces embryo aneuploidy: direct evidence from preimplantation genetic screening (PGS). Reprod Biol Endocrinol. 2010; 8:140. PMC: 2992540. DOI: 10.1186/1477-7827-8-140. View

19.

Yakin K, Urman B . DHEA as a miracle drug in the treatment of poor responders; hype or hope?. Hum Reprod. 2011; 26(8):1941-4. DOI: 10.1093/humrep/der150. View

20.

Casson P, Santoro N, Elkind-Hirsch K, Carson S, Hornsby P, Abraham G . Postmenopausal dehydroepiandrosterone administration increases free insulin-like growth factor-I and decreases high-density lipoprotein: a six-month trial. Fertil Steril. 1998; 70(1):107-10. DOI: 10.1016/s0015-0282(98)00121-6. View